Analyst Price Target is $4.00
▲ +627.40% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Processa Pharmaceuticals in the last 3 months. The average price target is $4.00, with a high forecast of $5.00 and a low forecast of $3.00. The average price target represents a 627.40% upside from the last price of $0.55.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Processa Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.